# DESCRIPTION

## BACKGROUND OF THE INVENTION

- define fibrosis
- describe idiopathic pulmonary fibrosis

## SUMMARY OF THE INVENTION

- introduce methods for prognosing fibrosis progression
- introduce methods for identifying compounds that slow down fibrosis progression
- introduce methods for monitoring therapy effectiveness
- introduce methods for selecting subjects for clinical trials
- introduce methods for inhibiting fibrosis progression
- describe TLR9 overexpression in IPF patients
- describe TLR9 upregulation by unmethylated CpG DNA motifs
- describe adoptive transfer model results
- describe CpG-induced fibrocyte-like cell differentiation
- describe CpG-mediated EMT in human A549 lung epithelial cells
- summarize invention aspects

## DETAILED DESCRIPTION OF THE INVENTION

- introduce background of TLR9 and fibrosis

### I. Definitions

- define articles "a" and "an"
- define fibrosis
- define fibrotic disorders
- define progression of fibrosis
- define rapid progressor
- define slow progressor
- define Toll-like receptor (TLR)
- define higher level of expression of TLR9
- define lower level of expression of TLR9
- define known standard level of TLR9
- define patient or subject
- define sample
- define slowed progression of fibrosis

### II. Uses of the Invention

- introduce prognostic methods for fibrosis
- determine TLR9 expression level in sample
- compare TLR9 expression with control sample
- describe sample types for TLR9 expression analysis
- outline techniques for obtaining samples
- isolate sub-components of fluid or tissue samples
- culture sample and determine responsiveness to TGFβ and CpG
- determine presence or absence of unmethylated CpG
- determine presence or absence of gammaherpesvirus
- determine level of expression of additional markers
- provide nucleotide and amino acid sequences of markers
- practice methods in conjunction with other fibrosis prognosis methods
- determine TLR9 expression using various techniques
- describe mRNA sample analysis methods
- outline probe design and use
- describe nucleic acid amplification and detection methods
- use microarrays to detect TLR9 expression
- detect TLR9 at protein level using antibodies
- describe protein isolation and detection methods
- use Western blots and immunofluorescence techniques
- use mass spectrometry and other proteomic methods
- identify compounds that slow down fibrosis progression
- describe screening assays for TLR9 modulators
- define TLR9 activity and biological responses
- list test compounds for screening assays
- describe methods for synthesizing molecular libraries
- present libraries of compounds
- evaluate test compounds for TLR9 modulation
- formulate compounds as pharmaceutical compositions
- analyze TLR9 structure for binding molecules
- identify compounds using computer-based analysis
- monitor therapy effectiveness in reducing fibrosis progression
- describe methods for selecting subjects for clinical trials
- determine TLR9 expression levels in subjects
- compare TLR9 expression levels to control samples
- inhibit fibrosis progression using TLR9 antagonists
- administer TLR9 antagonists to subjects
- define inhibiting fibrosis progression
- describe TLR9 antagonists
- define antibodies and antigen-binding portions
- describe bispecific and camelid antibodies
- introduce camelid nanobodies
- describe diabodies
- describe single chain diabodies
- describe di-diabodies
- introduce non-antibody binding molecules
- describe scaffold proteins
- describe generation of non-antibody binding molecules
- describe production of non-antibody binding molecules
- introduce antibody fragments and mimetics
- describe domain antibodies
- describe nanobodies
- describe unibodies
- describe adnectins
- describe aptamers
- describe peptide aptamers
- describe affibodies
- describe DARPins
- describe anticalins
- describe avimers and versabodies
- introduce SMIPs
- provide examples of immunoconjugate agents
- describe formation of immunoconjugates
- list bifunctional protein coupling agents
- describe preparation of ricin immunotoxin
- introduce TLR9 antagonists as small molecules
- describe characteristics of small molecules
- introduce antisense nucleic acid molecules
- describe design of antisense nucleic acid molecules
- describe construction of antisense nucleic acid molecules
- describe administration of antisense nucleic acid molecules
- introduce α-anomeric nucleic acid molecules
- introduce RNA interfering agents
- introduce ribozymes and fusion proteins as TLR9 antagonists
- describe uses of TLR9 antagonists
- pegylate TLR9 polypeptides with nonnatural amino acids
- combine TLR9 antagonists with other therapies
- administer TLR9 antagonists with co-therapeutic agents
- link TLR9 antagonists to second binding molecules
- define effective amount of TLR9 antagonists
- determine dosage regimens for TLR9 antagonists
- adjust dosage levels based on pharmacokinetic factors
- administer TLR9 antagonists via various routes
- formulate TLR9 antagonists with carriers and diluents
- prepare sterile injectable solutions and powders
- present formulations in unit dosage forms
- define parenteral administration modes
- use adjuvants and isotonic agents in formulations
- administer TLR9 antagonists with medical devices

### III. Kits of the Invention

- define kit components
- describe kit variations
- specify kit use

## EXAMPLES

### I. Materials and Methodologies

- introduce mice
- describe human-SCID model of AE-IPF
- introduce IPF patients
- describe cell culture and monocyte differentiation assay
- describe A549 cell culture and EMT assay
- describe siRNA knockdown of TLR9
- describe statistical analysis
- describe histological analysis of human-SCID model of IPF
- describe isolation and culture of primary pulmonary fibroblast lines
- describe preparation of RNA and cDNA from SLBs and primary pulmonary fibroblast lines
- describe real-time TaqMan PCR analysis

### Clinical Features of Rapid Versus Slowly Progressive Forms of IPF and Identification of Differential TLR9 Expression in Surgical Lung Biopsies

- describe clinical features of rapid versus slow IPF
- describe TLR9 expression in surgical lung biopsies

### CpG-ODN Induces a Fibroblast-Like Phenotype in Primary Human Blood Monocytes In Vitro in the Presence of TGFβ

- describe monocyte purification and culture
- describe morphological assessment of monocytes
- describe gene expression analysis of αSMA and collagen 1
- describe immunohistochemistry of collagen 1
- describe flow cytometric analysis of collagen 1 and CD14
- describe characterization of fibrocyte-like monocytes
- describe effects of CpG on CD14+ and CD14- monocyte populations

### CpG-ODN Induces Epithelial-Mesenchymal Transition in A549 Cells

- postulate CpG effects on epithelial cells
- describe A549 cell line and TGFβ-driven EMT
- test CpG treatment on A549 cells and assess morphological changes
- measure EMT marker expression and innate immune response
- determine TLR9 dependence of CpG-induced EMT

### TLR9 Expression and Response to CpG-ODN is Increased in Rapidly Progressive IPF

- examine TLR9 expression in lung fibroblasts from IPF patients
- measure cytokine production in response to CpG-ODN and IL-4
- compare TLR9 expression and response between rapid and slow progressors
- show differential expression pattern of TLR9 and response to CpG

## Discussion

- introduce idiopathic pulmonary fibrosis (IPF)
- describe pathogenesis of fibrotic disease
- discuss etiology of IPF disease progression
- highlight limitations of current treatments
- describe variability in disease progression
- discuss acute exacerbation of IPF (AE-IPF)
- motivate study of AE-IPF
- describe role of TLR9 in IPF
- discuss expression of TLR9 in IPF patients
- link TLR9 expression to rapid or slowly progressive phenotype
- describe inflammatory infiltrates in AE-IPF
- discuss markers of AE-IPF
- motivate study of TLR9 in fibrocytes
- summarize implications of TLR9 in IPF

## Example 6

### Primary Fibroblast Cultures Obtained from Subjects Having IPF May Be Used to Prognose Rapidly Progressive IPF

- describe use of primary fibroblast cultures to predict rapidly progressive IPF

## EQUIVALENTS

- discuss equivalents of the invention

